Key result
Vitamin B12 and sitagliptin inhibit tumor growth and extend survival in mice with solid tumors.
Why the study?
The study was conducted to investigate the potential effects of vitamin B12 and sitagliptin, and their possible synergistic effect with doxorubicin on the Ehrlich solid tumor model.
Does vitamin B12 and sitagliptin, alone or in combination with doxorubicin, inhibit tumor growth and increase survival in mice with Ehrlich solid tumors?
Does vitamin B12 and sitagliptin, alone or in combination with doxorubicin, inhibit tumor growth and increase survival in mice with Ehrlich solid tumors?
Sitagliptin and vitamin B12 demonstrate antitumor activity and potential synergy with doxorubicin in a mouse model of Ehrlich solid tumor, likely via apoptosis induction and suppression of oxidative stress and inflammation.
Answers are grounded in this paper and cite their sources.
Does not support clinical use in cancer; leaves open adjunctive potential in solid tumors pending human trials.
This study was carried out to investigate the potential effects of vitamin B12 and sitagliptin, and their possible synergistic effect with doxorubicin (DOX) on the Ehrlich solid tumor model. B12, sitagliptin, and their combination with DOX were administered to tumor-bearing mice for 21 days. Treatment with B12, sitagliptin, as well as their combinations with DOX caused a significant inhibition of tumor growth and increased the survival time. Malondialdehyde levels and the relative expression of tumor necrosis factor-α and nuclear factor kappa B were significantly decreased, whereas the total antioxidant capacity was significantly increased in all treated groups, except the DOX-treated one, when compared with the positive control group. Moreover, increased apoptosis was also observed by increased cleaved caspase-3 immunostaining and histopathological examination. In conclusion, the antitumor activity of B12 and sitagliptin could be attributed to their ability to induce apoptosis and suppress oxidative stress and inflammation.
No takes yet. Share an insight, caveat, or question.
Salah et al. (2020) studied Ehrlich ascites carcinoma solid tumor. Vitamin B12 and sitagliptin, alone or in combination with doxorubicin vs. Positive control group was evaluated on Tumor growth and survival time. Treatment with vitamin B12 and sitagliptin, alone or combined with doxorubicin, significantly inhibited tumor growth and increased survival time in mice with Ehrlich solid tumors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: